Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis

Drugs

Volumn 76, Issue 12, 2016, Pages 1191-1201

  Deeks, Emma D ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR PLUS LUMACAFTOR; PLACEBO; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; IVACAFTOR; LUMACAFTOR; QUINOLONE DERIVATIVE;

ARTICLE; BODY MASS; CELL SURFACE; CHLORIDE TRANSPORT; CLINICAL PRACTICE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; GENE MUTATION; HUMAN; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; DRUG EFFECTS; GENETICS; LUNG; MUTATION;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; LUNG; MUTATION; QUINOLONES;

EID: 84978032839     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-016-0611-2     Document Type: Article

References (53)

1. Cystic Fibrosis Foundation. About cystic fibrosis—what is cystic fibrosis? 2016. https://www.cff.org. Accessed 11 Mar 2016.
2. Bosch B, De Boeck K. Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell. Eur J Pediatr. 2016;175(1):1–8.
3. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891–904.
4. Galietta LJ. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors. Paediatr Drugs. 2013;15(5):393–402.
5. Griesenbach U, Alton EW. Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction. F1000Prime Rep. 2015;7:64.
6. CFTR.info. Classification of CFTR mutations. 2016. http://www.cftr.info. Accessed 19 May 2016.
7. Mayo Clinic. Disease and conditions: cystic fibrosis. 2016. http://www.mayoclinic.org. Accessed 11 Mar 2016.
8. Flume PA, Van Devanter DR. State of progress in treating cystic fibrosis respiratory disease. BMC Med. 2012;10:88.
9. Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros. 2014;13(Suppl 1):S23–42.
10. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–9.
11. Cytsic Fibrosis News Today. Cystic fibrosis statistics. 2016. http://cysticfibrosisnewstoday.com/cystic-fibrosis-statistics/. Accessed 11 Mar 2016.
12. Deeks ED. Ivacaftor: a review of its use in patients with cystic fibrosis. Drugs. 2013;73(14):1595–604.
13. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106(44):18825–30.
14. CFTR Science. Clinician’s guide to CFTR. CFTR mutations: 127 are known to be CF-causing. 2015. http://www.cftrscience.com/?q=cftr-mutations. Accessed 14 Mar 2016.
15. Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7(3):179–96.
16. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718–24.
17. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012;67(1):12–8.
18. Vertex Pharmaceuticals Incorporated. Orkambi™ (lumacaftor/ivacaftor) tablets, for oral use: US prescribing information. 2016. http://www.fda.gov/. Accessed 1 Jul 2016.
19. Vertex Pharmaceuticals (Europe) Limited. Orkambi 200 mg/125 mg film-coated tablets: EU summary of product characteristics. 2016. http://www.ema.europa.eu/. Accessed 1 Jul 2016.
20. Farinha CM, Sousa M, Canato S, et al. Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect. 2015;3(4):e00152.
21. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 2011;108(46):18843–8.
22. Ren HY, Grove DE, De La Rosa O, et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell. 2013;24(19):3016–24.
23. Kopeikin Z, Yuksek Z, Yang HY, et al. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J Cyst Fibros. 2014;13(5):508–14.
24. Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med. 2007;13(6):231–40.
25. Eckford PDW, Ramjeesingh M, Molinski S, et al. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol. 2014;21(5):666–78.
26. European Medicines Agency. Assessment report: Kalydeco (ivacaftor). 2012. http://www.ema.europa.eu. Accessed 17 Mar 2016.
27. Eckford PD, Li C, Ramjeesingh M, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem. 2012;287(44):36639–49.
28. Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012;11(3):237–45.
29. Van Goor F, Yu H, Burton B, et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13(1):29–36.
30. Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med. 2014;6(246):246ra97.
31. Matthes E, Goepp J, Carlile GW, et al. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor). Br J Pharmacol. 2016;173(3):459–70.
32. Cholon DM, Quinney NL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med. 2014;6(246):246ra96.
33. Marigowda G, Liu F, Waltz D. Effect of bronchodilators in healthy individuals receiving lumacaftor in combination with ivacaftor [abstract no. 256 plus poster]. Pediatr Pulmonol. 2014;49(S38):S307.
34. Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014;2(7):527–38.
35. Stanton BA, Coutermarsh B, Barnaby R, et al. Pseudomonas aeruginosa reduces VX-809 stimulated F508del-CFTR chloride secretion by airway epithelial cells. PLoS One. 2015;10(5):e0127742.
36. Robertson SM, Luo X, Dubey N, et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol. 2015;55(1):56–62.
37. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR. N Engl J Med. 2015;373(3):220–31 (plus supplementary appendix).
38. Konstan MW, Ramsey B, Elborn S, et al. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in patients with CF homozygous for F508del-CFTR [abstract no. 211]. Pediatr Pulmonol. 2015;50(Suppl 41):269–70.
39. Konstan MW, McKone EF, Moss RB, et al. Evidence for reduced rate of lung function decline and sustained benefit with combination lumacaftor and ivacaftor (LUM/IVA) therapy in patients (pts) 12 years of age with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation [poster no. 108]. In: 8th European Conference on Rare Diseases & Orphan Products; 2016.
40. 1 and incidence of pulmonary exacerbations, including those requiring hospitalization and/or IV antibiotics, in patients with CF treated with lumacaftor in combination with ivacaftor [abstract no. 241]. Pediatr Pulmonol. 2015;50(Suppl 41):282.
41. 1 subgroups [abstract no. 245]. Pediatr Pulmonol. 2015;50(Suppl 41):283–4.
42. Seliger V, Bai Y, Volkova N, et al. Prevalence of cataracts in a population of cystic fibrosis patients homozygous for the F508del mutation [abstract no. 196]. J Cyst Fibros. 2015;14(Suppl 1):S108.
43. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153(4):345–52.
44. Mayer M. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the ‘breakthrough’. Evid Based Med. 2016. doi:10.1136/ebmed-2015-110325.
45. Jones AM, Barry PJ. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Thorax. 2015;70(7):615–6.
46. Phuan PW, Veit G, Tan J, et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields DeltaF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol. 2014;86(1):42–51.
47. Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015;192(7):836–42.
48. Sawicki GS, McKone EF, Millar S, et al. Similar rates of lung function decline in patients with cystic fibrosis and the G551D or hmozygous F508DEL CFTR gene mutation [abstract no. 487]. In: North American Cystic Fibrosis Conference; 2015.
49. Rubin JL, Pelligra CG, Ward AJ, et al. Modeling the intermediate health outcomes of patients with CF who are homozygous for the F508DEL CFTR mutation treated with lumacaftor and ivacaftor combination therapy [abstract no. 236]. Pediatr Pulmonol. 2015;50(Suppl 41):280.
50. Rehman A, Baloch NU, Janahi IA. Correspondence: lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(18):1783.
51. Gulland A. Cystic fibrosis drug is not cost effective, says NICE. BMJ. 2016;353:i3409.
52. Vertex. FDA approves Orkambi™ (lumacaftor/ivacaftor)—the first medicine to treat the underlying cause of cystic fibrosis for people ages 12 and older with two copies of the F508del mutation [media release]. 2015. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=920512. Accessed 2 July 2015.
53. European Medicines Agency. Report of the workshop on endpoints for cystic fibrosis clinical trials. 2012. http://www.ema.europa.eu. Accessed 16 Mar 2016.